Epstein-Barr virus lives inside 95% of adults on Earth. You probably caught it as a teenager — it causes mono, hides inside your immune cells, and stays dormant for life. A landmark 2022 Harvard study tracking 10 million U.S. military personnel found that EBV infection increases the risk of developing multiple sclerosis by 32 times. Among the small group who never caught EBV, almost none developed MS. The virus isn’t just associated with the disease — it appears to be required for it.
Now a team at UC San Francisco led by Dr. Joe Sabatino has caught EBV in the act. Published February 5th, 2026, in Nature Immunology, their study examined CD8+ killer T cells — the assassins of the immune system that most MS research had overlooked in favor of CD4+ helper T cells. In MS patients, these killers were 10 to 100 times more concentrated in the cerebrospinal fluid than in blood, compared to an even distribution in healthy controls. Many of them specifically targeted Epstein-Barr virus. Most critically, the team found one specific EBV gene active only in MS patients — silent in healthy carriers of the same virus.
The emerging picture is devastating in its elegance. EBV partially reactivates in the nervous systems of MS patients, expressing a gene that provokes a massive immune response. Killer T cells flood in to attack the virus, and in the process, they cause collateral damage to the myelin coating on nerve fibers — like calling an airstrike on a building because there’s one enemy combatant inside. A separate Stanford study found that part of the EBV protein mimics a brain protein called GlialCAM, suggesting molecular mimicry may compound the direct viral provocation.
The therapeutic implications are enormous. Moderna has an mRNA vaccine against EBV in Phase 1 clinical trials — if it works, vaccinating teenagers before they encounter EBV could potentially prevent MS within a generation. For the nearly one million Americans already living with MS, researchers are exploring therapies to suppress the specific viral gene or clear EBV-infected cells from the nervous system. After six decades of investigating EBV since its discovery in 1964, science is finally connecting the dots from “weird correlation” to specific gene, specific cells, and specific mechanism.
There’s a virus living inside 95% of adults on Earth right now. You probably got it as a teenager. And a new study just found it may be actively attacking the nervous systems of people with multiple sclerosis.
Epstein-Barr virus - EBV. Most people know it as the virus that causes mono, the “kissing disease.” You catch it, you feel terrible for a few weeks, you recover, and the virus goes dormant in your body. It hides inside your B cells - a type of immune cell - and it stays there for life.
So MS - multiple sclerosis - is a disease where your immune system mistakenly attacks myelin. Myelin is the protective coating around nerve fibers in your brain and spinal cord. Think of it like the insulation around electrical wires. When that insulation gets stripped away, the signals misfire, slow down, or stop entirely.
It’s devastating. People with MS can experience fatigue, numbness, tingling, muscle weakness, vision problems, difficulty walking, cognitive issues, bladder problems. And it’s progressive - it typically gets worse over time. There are treatments that slow the progression, but there is no cure.
Most people are diagnosed between ages 20 and 40. It hits people in the prime of their lives. Women are about three times more likely to develop it than men. And the disease costs are staggering - the average lifetime cost per patient in the US is estimated at over 4 million dollars when you factor in medical care, lost wages, and reduced quality of life.
Nearly one million Americans live with it. Nearly one million Americans live with it. And here’s what’s been bugging scientists for decades - virtually every single person who develops MS is infected with EBV. Not 80%. Not 90%. Virtually 100%.
That’s the million-dollar question, and it’s why this took so long to crack. The landmark study came in January 2022 from Harvard. A team led by Alberto Ascherio published a paper in Science that followed 10 million U.S. military personnel over 20 years. They tracked who had EBV and who didn’t, and who developed MS.
The risk of developing MS increased 32-fold after EBV infection. 32 times higher. And in the small group of people who never got infected with EBV? Almost none of them developed MS. That was the smoking gun that EBV wasn’t just associated with MS - it was likely required for it.
32 times. That’s not a subtle association. But “required” still isn’t the same as “causes.” If 95% of people have EBV and only a fraction get MS, something else must be happening too.
Right - and that’s where the brand new study comes in. Published February 5th, 2026, in Nature Immunology, by a team at UC San Francisco led by Dr. Joe Sabatino. They found something that starts to explain the mechanism - how EBV actually triggers the disease in some people.
They looked at a type of immune cell that’s been largely overlooked in MS research - CD8+ killer T cells. These are the assassins of your immune system. Their job is to find and destroy cells that are infected or damaged.
Right. CD4+ T cells are the coordinators - they organize immune responses but don’t directly kill anything. They’re easier to study in animal models, so that’s where most of the attention went. But Sabatino’s team decided to look at the killers directly in human patients.
They analyzed blood and cerebrospinal fluid from 13 patients with MS or early signs of the disease, plus 5 people without MS as controls. They looked specifically at which CD8+ T cells recognized specific proteins in those fluids.
In people without MS, the distribution was even - similar numbers of these cells in the blood and in the cerebrospinal fluid. Normal. But in MS patients? The CD8+ killer T cells were 10 to 100 times more concentrated in the cerebrospinal fluid than in the blood.
Something is pulling them in, or something in the nervous system is making them multiply like crazy. And here’s the critical finding - some of those killer T cells specifically target Epstein-Barr virus.
That’s what the data suggests. They found EBV itself present in the cerebrospinal fluid of most study participants - both with and without MS. The virus was there either way. But here’s the key - they looked at which EBV genes were active.
One specific EBV gene was active only in people with MS. Not in the healthy controls. This suggests that in MS patients, the virus isn’t just hiding quietly - it’s doing something. It’s expressing a gene that may be driving the overactive immune response that characterizes the disease.
That’s a really important detail. So it’s not just the presence of the virus - it’s that the virus is doing something specific in MS patients that it’s not doing in healthy people.
Right. Same virus, same location, different behavior. Something about the MS environment - whether it’s genetic, immunological, or something else - allows or encourages EBV to activate this particular gene.
And those killer cells, in their frenzy to attack the virus, may be causing collateral damage to the myelin coating on nerve fibers. It’s like calling in an airstrike on a building because there’s one enemy combatant inside - you get the target, but you destroy the building too.
That’s a different mechanism, and it may also be at play. A Stanford study from 2022 found that part of the EBV protein mimics a protein made in the brain and spinal cord called GlialCAM. So you might have both things happening - direct viral provocation causing killer T cell invasion, AND molecular mimicry causing misdirected attacks.
That’s the big hope. And some researchers are already testing therapies that target EBV directly. Sabatino himself said - and I’m quoting - “The big hope here is that if we can interfere with EBV, we can have a big effect, not just on MS but on other disorders, and improve the quality of life for many, many people.”
Lupus, rheumatoid arthritis, long COVID, and several types of cancer including certain lymphomas and nasopharyngeal cancer. EBV is estimated to cause about 200,000 cancers globally every year.
And here’s something that could change everything - Moderna has an EBV vaccine in clinical trials right now. It’s an mRNA vaccine, similar technology to the COVID vaccines. If it works, you could potentially prevent MS before it ever starts by stopping the EBV infection that triggers it.
Frequently Asked Questions
Does Epstein-Barr virus cause multiple sclerosis?
A landmark 2022 study of 10 million U.S. military personnel found that EBV infection increases MS risk by 32-fold. Nearly all MS patients have been previously infected with EBV. While other cofactors exist, EBV appears to be a necessary (though not sufficient) trigger for MS development.
Could a vaccine prevent multiple sclerosis?
If EBV is confirmed as the primary trigger for MS, an EBV vaccine could potentially prevent most cases of multiple sclerosis. Moderna is developing an mRNA-based EBV vaccine currently in clinical trials. This could be one of the most impactful vaccines since polio if successful.
Related Episodes
If you enjoyed this episode, check out these related deep dives: